17.06.2021 14:01:28

Synlogic Partners Roche To Develop Synthetic Biotic Medicine For Inflammatory Bowel Disease

(RTTNews) - Synthetic biology firm Synlogic, Inc. (SYBX) announced Thursday that it has entered into a research collaboration agreement with Swiss drug major Roche Group (RHHBY) for the discovery of a novel Synthetic Biotic medicine for the treatment of inflammatory bowel disease (IBD).

Under the terms of the agreement, Synlogic and Roche will collaborate to develop a Synthetic Biotic medicine addressing an undisclosed novel target in IBD.

At the conclusion of the research period, Roche will have the exclusive option to enter a licensing and collaboration agreement for further development and commercialization of the program.

Analysen zu Roche Holding AG Sponsored American Deposit Receipt Repr 1/2 NVTGShmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel